Cybin Announces Conditional Listing Approval from NYSE American


TORONTO – Cybin Inc. ( NEO: CYBN) (OTCQB: CLXPF) (“Cybin” or “Company“), a biotech company focused on developing psychedelic therapies, announced today that it has received conditional listing approval from the stock exchange NYSE American LLC. (“NYSE American“).

Doug Drysdale, CEO of Cybin, added, “The approval of a conditional listing on NYSE American is an important milestone in Cybin’s growth journey. We look forward to expanding our access to investors to fuel our mission to develop revolutionary psychedelic therapy for patients with mental health conditions. ”


All listings are still subject to NYSE American approval and meeting all applicable regulatory requirements. There is no guarantee that an application will be approved. The company plans to maintain its current listing on the NEO Exchange. The company has reserved the ticker CYBN on NYSE American.

About Cybin

Cybin is a leading biotech company focused on developing psychedelic therapy using proprietary drug discovery platforms, innovative drug delivery systems, novel preparation methods and treatment regimens for mental disorders.

Note Warnings and Forward-looking Statements

Certain statements in this newsletter concerning the Company are forward-looking statements and are of a forward-looking nature. Forward-looking statements are not based on historical data, but on current expectations and projections of future events and are therefore subject to risks and uncertainties that could dictate the results. fact is distinct from future results expressed or implied by forward-looking statements. These statements can often be identified using forward-looking words such as “could”, “should”, “could”, “intend”, “estimate”, “plan”. “anticipate”, “expect”, “believe” or “continue”, or their negation or similar variations. Forward-looking statements in this newsletter include statements about the Company’s potential listing on the NYSE American. There are many risks and uncertainties that could cause actual results and Cybin’s plans and goals to differ significantly from those expressed in forward-looking information. Actual results and future events may differ significantly from those predicted in such information. These and all subsequent written and oral communications are based on the estimates and opinions of management as of the date they were made and are expressly endorsed by this notice as all information. Except as required by law, the Company does not intend to update these forward-looking statements.

Cybin makes no claims of medical, therapeutic, or health benefits about Cybin’s suggested products. The U.S. Food and Drug Administration, Health Canada, or other similar regulatory agencies have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives, or virtual compounds. sensory or nutritional products. The effectiveness of such products has not been confirmed by approved research. There is no guarantee that the use of psilocybin, hallucinogenic tryptamine, tryptamine derivatives or other psychedelic compounds or nutrients can diagnose, treat, cure or prevent any disease or what status. Strong scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any reference to the quality, consistency, effectiveness, and safety of potential products does not mean that Cybin has verified it in clinical trials or that Cybin will complete those trials. . If Cybin is unable to obtain the necessary approvals or research to commercialize its business, it could have a serious adverse effect on Cybin’s performance and operations.

NEO Exchange has not approved or disapproved the content of this news release and is not responsible for the completeness and accuracy of the contents herein.

See the source version on



Investor contact:
Tim Regan / Scott Eckstein
Strategic Communication KCSA

Lisa M. Wilson
In-Site Communications, Inc.

Vehicle directory:
John Kanakis
Cybin Inc.

#distro | Cybin Announces Conditional Listing Approval from NYSE American


Inter Reviewed is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – The content will be deleted within 24 hours.

Related Articles

Back to top button